Skip to content

13F-HR filed by RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL MANAGEMENT, L.P. filed this 13F-HR for the quarter ended 2018-06-30, filed 2018-08-14, with 27 holding rows worth $1,540,247,000.

Accession
0001144204-18-044712
Filed
2018-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2018

A holdings report, 27 entries on the cover page, a total value of $1,540,247,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,540,247,000 with VALUE read as thousands by filing date, 13F file number 028-12884. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
WAVE LIFE SCIENCES LTD SHSY95308105Stock7,512,049$287,336,000thousands by filing date
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR4,240,536$282,080,000thousands by filing date
SOLID BIOSCIENCES INC COM NEW83422E105Stock2,689,444$95,825,000thousands by filing date
ENDOCYTE INC29269A102COM5,649,884$77,968,000thousands by filing date
MOMENTA PHARMACEUTICALS INC60877T100COM3,702,533$75,717,000thousands by filing date
IMMUNOMEDICS INC452907108COM3,119,778$73,845,000thousands by filing date
MYOVANT SCIENCES LTDG637AM102COMMON STOCK-FO2,830,455$64,733,000thousands by filing date
Inflarx NvN44821101COM1,967,148$63,441,000thousands by filing date
TG THERAPEUTICS INC COM88322Q108Stock4,278,796$56,266,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM350,933$54,932,000thousands by filing date
ZOGENIX INC.98978L204Common Stock1,145,268$50,621,000thousands by filing date
RHYTHM PHARMACEUTICALS INC76243J105COM1,541,743$48,195,000thousands by filing date
DICERNA PHARMACEUTICALS INC253031108COM3,933,489$48,185,000thousands by filing date
EIDOS THERAPEUTICS INC.28249H104Common Stock2,162,671$43,989,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock6,984,692$40,022,000thousands by filing date
RA PHARMACEUTICALS INC74933V108COM3,851,808$38,325,000thousands by filing date
KALA BIO INC COM483119103Stock2,113,236$29,015,000thousands by filing date
APELLIS PHARMACEUTICALS INC03753U106COM900,000$19,800,000thousands by filing date
CLEARSIDE BIOMEDICAL INC185063104COM1,525,000$16,302,000thousands by filing date
SCPHARMACEUTICALS INC810648105COM2,857,143$16,171,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM1,121,153$14,351,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM1,441,070$11,701,000thousands by filing date
AVEO PHARMACEUTICALS INC053588109COM5,062,759$11,442,000thousands by filing date
SPERO THERAPEUTICS INC84833T103COM741,647$10,880,000thousands by filing date
GLYCOMIMETICS INC38000Q102COM253,547$4,090,000thousands by filing date
PROTEON THERAPEUTICS INC74371L109COM1,337,462$3,277,000thousands by filing date
G1 THERAPEUTICS INC3621LQ109COM40,000$1,738,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001144204-18-044712this filing2018-08-14acceptance time not in the bulk data set